Immunome, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Immunome, Inc. (IMNM) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $89.80 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-11
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $89.80M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $81.70M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $81.50M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $87.40M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $89.80M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $81.70M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $81.50M 10-K · filed 2026-03-03 |
| 2025-09-30 | $87.40M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $62.90M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $68.20M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $75.20M 10-K · filed 2025-03-19 |
| 2024-09-30 | $72.20M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $43.70M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $37.10M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $22.80M 10-K · filed 2024-03-28 |
| 2023-09-30 | $7.40M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $8.40M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $7.60M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $9.20M 10-K · filed 2023-03-16 |
| 2022-09-30 | $10.50M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $12.10M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $12.10M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $13.30M 10-K · filed 2022-03-28 |
| 2021-09-30 | $13.50M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $12.90M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $7.30M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $3.60M 10-K · filed 2021-03-25 |
| 2020-09-30 | $1.50M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |